New Horizons: Allergen-Specific Immunotherapy and Allergy Vaccination

Allergies are a global public health problem affecting millions of people worldwide and significantly reducing their quality of life. From mild symptoms such as a runny nose and itching to life-threatening conditions such as anaphylaxis and severe asthma, allergic reactions are caused by an overactive immune response to harmless substances—allergens. At the core of many allergic diseases is the production of immunoglobulin E (IgE) class antibodies, which trigger a cascade of inflammatory reactions.

Allergen-specific immunotherapy (AIT) is the only treatment capable of altering the natural course of allergic disease rather than simply relieving symptoms. However, researchers are constantly searching for ways to improve its safety and efficacy [1].

Allergen-Specific Immunotherapy: From Basics to Innovations

Traditional AIT consists of the gradual administration of increasing doses of an allergen to the patient's body in order to "retrain" the immune system and induce tolerance. The goals of such therapy are multifaceted: reducing symptom severity, decreasing the need for anti-allergic medications, preventing the development of new sensitizations, and halting disease progression, such as the transition from allergic rhinitis to bronchial asthma.

Despite its proven efficacy, traditional AIT has its limitations, including the long duration of the treatment course and the risk of adverse reactions. Therefore, key areas of modern research focus on increasing safety while maintaining or even enhancing efficacy [1].

Innovative Strategies to Enhance Efficacy and Safety of AIT

Current scientific developments focus on creating more advanced vaccines and treatment regimens within AIT. These strategies include:

• Allergen Modification: Allergens can be linked to innate immunostimulatory substances or novel adjuvants, which helps enhance the immune response. Modified allergens are also being developed to improve their uptake and presentation by immune cells, contributing to more effective tolerance induction [1].
• Hypoallergenic Molecules: To improve the safety profile of vaccines and minimize undesirable adverse reactions, hypoallergenic molecules are being developed. This helps reduce the risk of allergic reactions during the therapy itself, making it more comfortable for patients [1].

Targeted IgE Combat: The Concept of Allergy Vaccination

Immunoglobulin E (IgE) plays a central role in the development of allergic reactions. High levels of total and specific IgE are closely associated with symptom severity in atopic patients [2]. For example, a child with severe asthma following earthquake-related inhalational dust exposure showed significantly elevated total IgE levels (1664 kIU/L) [6]. Allergic asthma is often associated with a Th2 immune response, which leads to the production of cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13), promoting IgE production and inflammation [7].

Based on this, scientists hypothesized that a substantial reduction in both total and antigen-specific IgE levels would improve the condition of atopic patients [2]. Studies were initiated to investigate the possibility of lowering circulating and mast cell-bound IgE levels by inducing a strong autoimmune response against IgE in the body. Bacterial-produced fusion proteins containing rat IgE constant domains (CH2 and CH3) directly linked to glutathione S-transferase (GST) or maltose-binding protein were used as active components of the "allergy vaccine" [2].

Injections of these fusion proteins along with an adjuvant induced a strong autoimmune response against IgE in several rat strains. Vaccination of ovalbumin-sensitized rats with the GST-C2C3 fusion protein resulted in a significant reduction in serum IgE levels, demonstrating the potential of this approach in combating allergies [2].

Passive Immunization: A Fast Track to Relief

In addition to active strategies aimed at "retraining" the immune system, passive immunization methods are also being developed. One such new and rapid approach is the administration of recombinant IgG4 antibodies [1]. These antibodies can directly block allergic reactions by binding to allergens or IgE, thereby preventing mast cell activation and the release of inflammatory mediators. This allows for a rapid and noticeable effect, which is particularly important in cases requiring immediate symptom relief [1].

The Future of Allergology: Personalization and New Horizons

Research in the field of allergen-specific immunotherapy and vaccination continues to evolve, promising new, safer, more effective, and faster allergy treatments. From allergen modification and the use of novel adjuvants to targeted IgE combat and passive immunization, all these avenues pave the way toward personalized medicine, where treatment will be maximally tailored to the individual needs of each patient. Further development of these strategies will significantly improve the quality of life for people suffering from allergic diseases.

Sources

• 1. Highlights of Novel Vaccination Strategies in Allergen Immunotherapy. (Immunology and allergy clinics of North America, 2020) PubMed
• 2. Is vaccination against IgE possible? (Advances in experimental medicine and biology, 1996) PubMed
• 6. Case Report: Severe asthma following earthquake-related inhalational exposure in a child. (Frontiers in pediatrics, 2026) PubMed
• 7. Bronchodilatory effect of higenamine as antiallergic asthma treatment. (Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022) PubMed

The information presented in the article is for reference purposes only and cannot replace an in-person consultation with a physician. Always seek medical care from qualified specialists.